BCHE and Alzheimer disease: In the context of AD, chalcones and their derivatives have shown pharmacological potentials against multiple targets by inhibiting both Aβ-fibrils aggregation and the activity of enzymatic systems such as acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), and pseudocholinesterase as well.